Atlas Trials

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Clinical trial NCT04172675 · COMPLETED

Trial details

NCT number
NCT04172675
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Urinary Bladder Neoplasms
Start date
2020-02-28
Primary completion
2024-07-12
Enrollment
107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.